To address if aT-bASCs de-differentiate into a myofibroblastic cancer-associated (myCAF) phenotype, we assessed their specific protein markers alpha-smooth muscle actin (αSMA), fibroblast-specific protein1 (FSP1) and integrin subunit beta 1 (CD29) by flow cytometry. This evidence concerns the gene ITGB1 and cancer.